1,061 results match your criteria Advances in cancer research[Journal]


Preface.

Adv Cancer Res 2020 ;146:xv-xx

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0065-230X(20)30030-0DOI Listing
January 2020

BMI, physical activity, and breast cancer subtype in white, black, and Sea Island breast cancer survivors.

Adv Cancer Res 2020 12;146:83-102. Epub 2020 Mar 12.

The National Coalition of Independent Scholars, San Antonio, TX, United States.

Higher BMI, lower rates of physical activity (PA), and hormone receptor-negative breast cancer (BC) subtype are associated with poorer BC treatment outcomes. We evaluated the prevalence of high BMI, low PA level, and BC subtype among survivors with white/European American (EA) and African American (AA) ancestry, as well as a distinct subset of AAs with Sea Island/Gullah ancestry (SI). We used the South Carolina Central Cancer Registry to identify 137 (42 EAs, 66 AAs, and 29 SIs) women diagnosed with BC and who were within 6-21 months of diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.005DOI Listing
March 2020
5.321 Impact Factor

Pubertal mammary development as a "susceptibility window" for breast cancer disparity.

Adv Cancer Res 2020 9;146:57-82. Epub 2020 Mar 9.

Department of Pathology & Laboratory Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address:

Factors such as socioeconomic status, age at menarche and childbearing patterns are components that have been shown to influence mammary gland development and establish breast cancer disparity. Pubertal mammary gland development is selected as the focus of this review, as it is identified as a "window of susceptibility" for breast cancer risk and disparity. Here we recognize non-Hispanic White, African American, and Asian American women as the focus of breast cancer disparity, in conjunction with diets associated with changes in breast cancer risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.004DOI Listing

Age-related disparities in older women with breast cancer.

Adv Cancer Res 2020 29;146:23-56. Epub 2020 Feb 29.

Washington University in St. Louis School of Medicine, St. Louis, MO, United States. Electronic address:

Improvements in breast cancer (BC) mortality rates have not been seen in the older adult community, and the fact that older adults are more likely to die from their cancer than younger women establishes a major health disparity. Studies have identified that despite typically presenting with more favorable histology, older women present with more advanced disease, which may be related in part to delayed diagnosis. This is supported by examination of screening practices in older adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.003DOI Listing
February 2020

A primer for cancer research programs on defining and evaluating the catchment area and evaluating minority clinical trials recruitment.

Adv Cancer Res 2020 14;146:219-226. Epub 2020 Mar 14.

Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

National Cancer Institute (NCI) designated cancer centers are charged with reducing disparities, improving cancer-related health outcomes, and increasing clinical trial participation for the catchment area population. Succeeding in this endeavor requires a clear definition of each cancer center's geographic catchment area as well as the demographic characteristics of the populations residing in the catchment area. For this reason, the definition of the catchment area is now a required element of NCI grant applications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.02.001DOI Listing

Mighty men: A faith-based weight loss intervention to reduce cancer risk in African American men.

Adv Cancer Res 2020 24;146:189-217. Epub 2020 Feb 24.

Center for Research on Men's Health, Vanderbilt University, Nashville, TN, United States.

According to the American Cancer Society's guidelines on nutrition and physical activity for cancer prevention, weight control, eating practices and physical activity are second only to tobacco use as modifiable determinants of cancer risk. However, no evidence-based interventions have been targeted to African American men or tailored to individual African American men's preferences, needs or identities. The goal of this chapter is to describe the rationale for the components, aims and setting of Mighty Men: A Faith-Based Weight Loss Intervention for African American Men. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.010DOI Listing
February 2020

Project PLACE: Enhancing community and academic partnerships to describe and address health disparities.

Adv Cancer Res 2020 19;146:167-188. Epub 2020 Mar 19.

Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, United States.

Achieving cancer health equity is a national imperative. Cancer is the second leading cause of death in the United States and in North Carolina (NC), where the disease disproportionately impacts traditionally underrepresented race and ethnic groups, those who live in rural communities, the impoverished, and medically disenfranchised and/or health-disparate populations at high-risk for cancer. These populations have worse cancer outcomes and are less likely to be participants in clinical research and trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.009DOI Listing

Patient barriers to cancer clinical trial participation and navigator activities to assist.

Adv Cancer Res 2020 24;146:139-166. Epub 2020 Feb 24.

University of South Carolina, Arnold School of Public Health, Columbia, SC, United States.

Clinical research is vital to the discovery of new cancer treatments that can enhance health and prolong life for cancer patients, but breakthroughs in cancer treatment are limited by challenges recruiting patients into cancer clinical trials (CT). Only 3-5% of cancer patients in the United States participate in a cancer CT and there are disparities in CT participation by age, race and gender. Strategies such as patient navigation, which is designed to provide patients with education and practical support, may help to overcome challenges of CT recruitment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.008DOI Listing
February 2020
5.321 Impact Factor

Assessing an intervention to increase knowledge related to cervical cancer and the HPV vaccine.

Adv Cancer Res 2020 12;146:115-137. Epub 2020 Mar 12.

Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, United States.

Human papillomavirus (HPV) infection is the primary risk factor for cervical cancer. While the HPV vaccine significantly reduces the risk of HPV infection and subsequent cervical cancer diagnosis, underuse is linked to lack of knowledge of its effectiveness in preventing cervical cancer. The purpose of this study was to evaluate a cancer educational intervention (titled "MOVENUP") to improve knowledge of cervical cancer, HPV, and the HPV vaccine among predominantly African American communities in South Carolina. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.007DOI Listing
March 2020
5.321 Impact Factor

Race differences in mobility status among prostate cancer survivors: The role of socioeconomic status.

Adv Cancer Res 2020 24;146:103-114. Epub 2020 Feb 24.

Program for Research on Men's Health, Hopkins Center for Health Disparities Solutions, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Department of Health Policy and Management, Tulane School of Public Health and Tropical Medicine, New Orleans, LA, United States.

The objective of this paper was to determine whether there were any race differences in mobility limitation among PCa survivors, and understand the impact of socioeconomic status (SES) on this relationship. Data consisted of 661 PCa survivors (296 Black and 365 White) from the Diagnosis and Decisions in Prostate Cancer Treatment Outcomes (DAD) Study. Mobility limitation was defined as PCa survivors who reported difficulty walking a quarter mile or up 1 flight of stairs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.006DOI Listing
February 2020

Racial/ethnic disparities in ovarian cancer research.

Adv Cancer Res 2020 24;146:1-21. Epub 2020 Feb 24.

Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, United States.

Ovarian cancer is one of the most fatal cancers diagnosed in women in the United States (U.S.). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.002DOI Listing
February 2020

The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy.

Adv Cancer Res 2020 14;145:99-138. Epub 2020 Feb 14.

Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg. Electronic address:

Chemokines regulate directed cell migration, proliferation and survival and are key components in cancer biology. They exert their functions by interacting with seven-transmembrane domain receptors that signal through G proteins (GPCRs). A subgroup of four chemokine receptors known as the atypical chemokine receptors (ACKRs) has emerged as essential regulators of the chemokine functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.12.001DOI Listing
February 2020

Targeting G protein-coupled receptors in cancer therapy.

Adv Cancer Res 2020 20;145:49-97. Epub 2019 Dec 20.

Institute of Molecular Medicine, Sechenov First Moscow State Medical University, Moscow, Russian Federation; Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russian Federation. Electronic address:

As basic research into GPCR signaling and its association with disease has come into fruition, greater clarity has emerged with regards to how these receptors may be amenable to therapeutic intervention. As a diverse group of receptor proteins, which regulate a variety of intracellular signaling pathways, research in this area has been slow to yield tangible therapeutic agents for the treatment of a number of diseases including cancer. However, recently such research has gained momentum based on a series of studies that have sought to define GPCR proteins dynamics through the elucidation of their crystal structures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.11.002DOI Listing
December 2019

The G protein coupled receptor CCR5 in cancer.

Adv Cancer Res 2020 10;145:29-47. Epub 2020 Jan 10.

Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center, Wynnewood, PA, United States; Wistar Institute, Philadelphia, PA, United States; Xavier University School of Medicine, Woodbury, NY, United States. Electronic address:

The G coupled protein receptor CC chemokine receptor type 5 (CCR5) has the unusual characteristic in humans of being a developmentally non-essential gene that participates in several pathological processes including infection with HIV (Dean et al., 1996; Gupta et al., 2019; Samson et al. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.11.001DOI Listing
January 2020

Structure and function of β-arrestins, their emerging role in breast cancer, and potential opportunities for therapeutic manipulation.

Adv Cancer Res 2020 5;145:139-156. Epub 2020 Feb 5.

Department of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India.

β-Arrestins (βarrs) are multifunctional intracellular proteins with an ability to directly interact with a large number of cellular partners including the G protein-coupled receptors (GPCRs). βarrs contribute to multiple aspects of GPCR signaling, trafficking and downregulation. Considering the central involvement of GPCR signaling in the onset and progression of diverse types of cancers, βarrs have also emerged as key players in the context of investigating cancer phenotypes, and as potential therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2020.01.001DOI Listing
February 2020

Atypical chemokine receptors in tumor cell growth and metastasis.

Adv Cancer Res 2020 27;145:1-27. Epub 2020 Jan 27.

LCMB Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

Atypical chemokine receptors (ACKRs) are seven-transmembrane cell surface protein receptors expressed in immune cells, normal mesenchymal cells, and several tumor cells. As of this writing, six ACKRs have been characterized by diverse activities. They bind both cysteine-cysteine (CC) type and cysteine-X-cysteine (CXC)-type chemokines, either alone, or together with a ligand bound-functional G-protein coupled (typical) chemokine receptor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.12.002DOI Listing
January 2020

Clinical and translational advances in esophageal squamous cell carcinoma.

Adv Cancer Res 2019 10;144:95-135. Epub 2019 Jun 10.

Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States; Department of Pathology & Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States. Electronic address:

Esophageal squamous cell carcinoma (ESCC) is among the most deadly forms of human malignancy characterized by late stage diagnosis, metastasis, therapy resistance and frequent recurrence. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics. However, emerging data from recent clinical and translational investigations hold great promise for future progress toward improving patient outcomes in this deadly disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.05.004DOI Listing
June 2019
4 Reads

PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer.

Adv Cancer Res 2019 12;144:55-93. Epub 2019 Apr 12.

Fels Institute for Cancer Research and Molecular Biology and Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States. Electronic address:

PP2A is a highly conserved eukaryotic serine/threonine protein phosphatase of the PPP family of phosphatases with fundamental cellular functions. In cells, PP2A targets specific subcellular locations and substrates by forming heterotrimeric holoenzymes, where a core dimer consisting of scaffold (A) and catalytic (C) subunits complexes with one of many B regulatory subunits. PP2A plays a key role in positively and negatively regulating a myriad of cellular processes, as it targets a very sizable fraction of the cellular substrates phosphorylated on Ser/Thr residues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.009DOI Listing

Racial disparities, cancer and response to oxidative stress.

Adv Cancer Res 2019 23;144:343-383. Epub 2019 Apr 23.

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, United States.

At the intersection of genetics, biochemistry and behavioral sciences, there is a largely untapped opportunity to consider how ethnic and racial disparities contribute to individual sensitivity to reactive oxygen species and how these might influence susceptibility to various cancers and/or response to classical cancer treatment regimens that pervasively result in the formation of such chemical species. This chapter begins to explore these connections and builds a platform from which to consider how the disciplines can be strengthened further. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104807PMC
April 2019
2 Reads

Cancer stem cells in breast and prostate: Fact or fiction?

Adv Cancer Res 2019 13;144:315-341. Epub 2019 Jun 13.

Division of Biological Systems and Engineering, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. Electronic address:

Since the introduction of the cancer stem cell (CSC) hypothesis, accumulating evidence shows that most cancers present stem-like niches. However, therapies aimed at targeting this niche have not been as successful as expected. New evidence regarding CSCs hierarchy, similarities with normal tissue stem cells and cell plasticity might be key in understanding their role in cancer biology and how to efficiently eliminate them. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.010DOI Listing
June 2019
1 Read

Marine natural products in the discovery and development of potential pancreatic cancer therapeutics.

Adv Cancer Res 2019 6;144:299-314. Epub 2019 Jun 6.

Departments of Drug Discovery, Biomedical Sciences, and Public Health Sciences, Hollings Cancer Center, College of Pharmacy, Medical University of South Carolina, Charleston, SC, United States. Electronic address:

Pancreatic cancer one of the most deadly cancers and is an increasingly significant concern for global health. The death rates for pancreatic cancer have changed little over time, even with recent expansions of first-line drugs to treat pancreatic cancer there has been little improvement in patient prognosis. Any improvements in treatment strategies will come as a much-needed reprieve to patients diagnosed with this uniquely-challenging disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.05.003DOI Listing
June 2019
3 Reads

Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs.

Adv Cancer Res 2019 ;144:263-298

Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV, United States. Electronic address:

Cytotoxic chemotherapy is the mainstay of cancer treatment. Conventional chemotherapeutic agents do not distinguish between normal and neoplastic cells. This leads to severe toxic side effects, which may necessitate the discontinuation of treatment in some patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.05.002DOI Listing
January 2019
1 Read

Expression of costimulatory and inhibitory receptors in FoxP3 regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches.

Adv Cancer Res 2019 6;144:193-261. Epub 2019 Jun 6.

The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Immunology, University of Toronto, Toronto, ON, Canada. Electronic address:

The unprecedented success of immune checkpoint inhibitors has given rise to a rapidly growing number of immuno-oncology agents undergoing preclinical and clinical development and an exponential increase in possible combinations. Defining a clear rationale for combinations by identifying synergies between immunomodulatory pathways has therefore become a high priority. Immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment (TME) represent a major roadblock to endogenous and therapeutic tumor immunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.05.001DOI Listing

MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis.

Adv Cancer Res 2019 24;144:137-191. Epub 2019 Apr 24.

Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. Electronic address:

With few exceptions, metastasis is the terminal stage of cancer with limited therapeutic options. Metastasis consists of numerous phenotypic and genotypic alterations of cells that are directly and indirectly induced by multiple intrinsic (cellular) and extrinsic (micro-environmental) factors. To metastasize, a cancer cell often transitions from an epithelial to mesenchymal morphology (EMT), modifies the extracellular matrix, forms emboli and survives in the circulation, escapes immune surveillance, adheres to sites distant from the initial tumor and finally develops a blood supply (angiogenesis) and colonizes in a secondary niche (a micrometastasis). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.011DOI Listing
April 2019
2 Reads

Macroenvironment-gene-microenvironment interactions in ultraviolet radiation-induced melanomagenesis.

Adv Cancer Res 2019 23;144:1-54. Epub 2019 Apr 23.

Fels Institute for Cancer Research and Molecular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States. Electronic address:

Cutaneous malignant melanoma is one of the few major cancers that continue to exhibit a positive rate of increase in the developed world. A wealth of epidemiological data has undisputedly implicated ultraviolet radiation (UVR) from sunlight and artificial sources as the major risk factor for melanomagenesis. However, the molecular mechanisms of this cause-and-effect relationship remain murky and understudied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.008DOI Listing

Preface.

Adv Cancer Res 2019 ;143:xiii-xv

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0065-230X(19)30049-1DOI Listing
January 2019
3 Reads

From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy.

Adv Cancer Res 2019 28;143:63-144. Epub 2019 Apr 28.

Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address:

Cancer is a worldwide medical problem with significant repercussions on individual patients and societies as a whole. In order to alter the outcomes of this deadly disease the treatment of cancer over the centuries has undergone a unique evolution. However, utilizing the best treatment modalities and achieving cures or long-term durable responses have been inconsistent and limited, that is until recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.002DOI Listing
April 2019
2 Reads

Can CpG methylation serve as surrogate markers for immune infiltration in cancer?

Adv Cancer Res 2019 17;143:351-384. Epub 2019 Apr 17.

Department of Human and Molecular Genetics, VCU Institute of Molecular Medicine, VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. Electronic address:

Recent reports describe how genome-wide transcriptional analysis of cancer tissues can be exploited to identify molecular signatures of immune infiltration in cancer. We hypothesize that immune infiltration in cancer may also be defined by changes in certain epigenetic signatures. In this context, a primary objective is to identify site-specific CpG markers whose levels of methylation may be highly indicative of known transcriptional markers of immune infiltration such as GZMA, PRF1, T cell receptor genes, PDCD1, and CTLA4. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0065230X193002
Publisher Site
http://dx.doi.org/10.1016/bs.acr.2019.03.007DOI Listing
April 2019
32 Reads

Immunotherapy in breast cancer: Current status and future directions.

Adv Cancer Res 2019 2;143:295-349. Epub 2019 May 2.

Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States; Department of Breast Oncology, Moffitt Cancer Center, Tampa, FL, United States; University of South Florida, Tampa, FL, United States. Electronic address:

Breast cancer, one of the leading causes of death in women in the United States, challenges therapeutic success in patients due to tumor heterogeneity, treatment resistance, metastasis and disease recurrence. Knowledge of immune system involvement in normal breast development and breast cancer has led to extensive research into the immune landscape of breast cancer and multiple immunotherapy clinical trials in breast cancer patients. However, poor immunogenicity and T-cell infiltration along with heightened immunosuppression in the tumor microenvironment have been identified as potential challenges to the success of immunotherapy in breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.006DOI Listing
May 2019
16 Reads

Impact of the microbiome on cancer progression and response to anti-cancer therapies.

Adv Cancer Res 2019 17;143:255-294. Epub 2019 Apr 17.

Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA, United States. Electronic address:

Humans are a colonized with trillions of commensal microorganisms which exert a profound effect on normal host physiology and immune function through an abundance of genetic and metabolic by-products. Although the commensal microbiome has beneficial functions to host physiology, perturbations of the composition of the commensal microbiome or the homeostatic mucosal environment can lead to the induction of immune pathology and systemic inflammation. In the context of cancer progression or response to immune therapy, this inflammation can be detrimental, resulting in tumor growth and the promotion of immune suppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.005DOI Listing
April 2019
19 Reads

Immunometabolism: A new target for improving cancer immunotherapy.

Adv Cancer Res 2019 17;143:195-253. Epub 2019 Apr 17.

Department of Human & Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. Electronic address:

Fundamental metabolic pathways are essential for mammalian cells to provide energy, precursors for biosynthesis of macromolecules, and reducing power for redox regulation. While dysregulated metabolism (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822174PMC
April 2019
16 Reads

Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Adv Cancer Res 2019 17;143:145-194. Epub 2019 Apr 17.

Department of Microbiology and Immunology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, United States. Electronic address:

Cancer remains the leading cause of death worldwide. Traditional treatments such as surgery, radiation, and chemotherapy have had limited efficacy, especially with late stage cancers. Cancer immunotherapy and targeted therapy have revolutionized how cancer is treated, especially in patients with late stage disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.003DOI Listing
April 2019
2 Reads

Translation of cancer immunotherapy from the bench to the bedside.

Adv Cancer Res 2019 2;143:1-62. Epub 2019 May 2.

Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada; Jewish General Hospital, Segal Cancer Centre, Department of Oncology, Montreal, QC, Canada; Rossy Cancer Network, Montreal, QC, Canada. Electronic address:

The tremendous success of immune checkpoint blockades has revolutionized cancer management. Our increased understanding of the cell types that compose the tumor microenvironment (TME), including those of the innate and adaptive immune system, has helped to shape additional immune modulatory strategies in cancer care. Pre-clinical and clinical investigations targeting novel checkpoint interactions and key pathways that regulate cancer immunity continue to increase rapidly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.03.001DOI Listing
May 2019
11 Reads

The second genome: Effects of the mitochondrial genome on cancer progression.

Adv Cancer Res 2019 27;142:63-105. Epub 2019 Feb 27.

Department of Cancer Biology, The University of Kansas Medical Center, and The University of Kansas Cancer Center, Kansas City, KS, United States. Electronic address:

The role of genetics in cancer has been recognized for centuries, but most studies elucidating genetic contributions to cancer have understandably focused on the nuclear genome. Mitochondrial contributions to cancer pathogenesis have been documented for decades, but how mitochondrial DNA (mtDNA) influences cancer progression and metastasis remains poorly understood. This lack of understanding stems from difficulty isolating the nuclear and mitochondrial genomes as experimental variables, which is critical for investigating direct mtDNA contributions to disease given extensive crosstalk exists between both genomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921473PMC
May 2020
3 Reads

Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations.

Adv Cancer Res 2019 27;142:23-62. Epub 2019 Feb 27.

Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address:

Altered metabolism is one of the hallmarks of cancer. The best-known cancer metabolic anomaly is an increase in aerobic glycolysis, which generates ATP and other basic building blocks, such as nucleotides, lipids, and proteins to support tumor cell growth and survival. Epithelial plasticity (EP) programs such as the epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) are evolutionarily conserved processes that are essential for embryonic development. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0065230X193001
Publisher Site
http://dx.doi.org/10.1016/bs.acr.2019.01.002DOI Listing
May 2020
20 Reads

Pharmacology of ME-344, a novel cytotoxic isoflavone.

Adv Cancer Res 2019 6;142:187-207. Epub 2019 Mar 6.

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC, United States. Electronic address:

Isoflavones isolated from members of the Fabaceae (primarily Leguminosae) family have been characterized for their phytoestrogenic properties, but certain derivatives have also shown potential as possible cancer therapeutic agents. ME-344, related to phenoxodiol (Fig. 1), is a second generation isoflavone with a recent history of both preclinical and early clinical testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.01.005DOI Listing
May 2020
4 Reads

HVEM network signaling in cancer.

Adv Cancer Res 2019 27;142:145-186. Epub 2019 Feb 27.

Infectious and Inflammatory Disease Center, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

Somatic mutations in cancer cells may influence tumor growth, survival, or immune interactions in their microenvironment. The tumor necrosis factor receptor family member HVEM (TNFRSF14) is frequently mutated in cancers and has been attributed a tumor suppressive role in some cancer contexts. HVEM functions both as a ligand for the lymphocyte checkpoint proteins BTLA and CD160, and as a receptor that activates NF-κB signaling pathways in response to BTLA and CD160 and the TNF ligands LIGHT and LTα. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.01.004DOI Listing
May 2020
3 Reads

Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors.

Adv Cancer Res 2019 6;142:107-143. Epub 2019 Mar 6.

3R Biosystems, Long Beach, CA, United States.

Recent clinical studies document the power of immunotherapy in treating subsets of patients with advanced cancers. In this context and with multiple cancer immunotherapeutics already evaluated in the clinic and a large number in various stages of clinical trials, it is imperative to comprehensively examine genomics data to better comprehend the role of immunity in different cancers in predicting response to therapy and in directing appropriate therapies. The approach we chose is to scrutinize the pathways and epigenetic factors predicted to drive immune infiltration in different cancer types using publicly available TCGA transcriptional and methylation datasets, along with accompanying clinico-pathological data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.01.003DOI Listing
May 2020
5 Reads

Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patients.

Adv Cancer Res 2019 27;142:1-22. Epub 2019 Feb 27.

Fels Institute of Cancer Research and Molecular Biology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, United States. Electronic address:

The "CpG Island Methylator Phenotype" (CIMP) has been found to be a useful concept in stratifying several types of human cancer into molecularly and clinically distinguishable subgroups. We have identified an additional epigenetic stratification category, the "Outlier Methylation Phenotype" (OMP). Whereas CIMP is defined on the basis of hyper-methylation in tumor genomes, OMP is defined on the basis of highly variant (either or both hyper- and hypo-methylation) methylation at many sites in normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2019.01.006DOI Listing
May 2020
2 Reads

Preface.

Adv Cancer Res 2019 ;141:xi-xiii

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0065-230X(19)30008-9DOI Listing
April 2020
5 Reads

Clonal hematopoiesis: Pre-cancer PLUS.

Adv Cancer Res 2019 14;141:85-128. Epub 2019 Jan 14.

Department of Pathology, Stanford University, Stanford, CA, United States. Electronic address:

Clonal hematopoiesis is a common, age-related process in which a somatically mutated hematopoietic precursor gives rise to a genetically distinct subpopulation in the blood. This phenomenon has been observed in populations across the globe and, while virtually non-existent in children is estimated to affect >10% of the 70-and-older age group. The mutations are thought to occur in stem cells, which makes them pre-cancerous, and precursors to cancer stem cells. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0065230X183007
Publisher Site
http://dx.doi.org/10.1016/bs.acr.2018.12.003DOI Listing
April 2020
48 Reads

Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting.

Adv Cancer Res 2019 16;141:43-84. Epub 2019 Jan 16.

Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; VCU Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States; VCU Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. Electronic address:

Dormancy occurs when cells remain viable but stop proliferating. When most of a cancer population undergoes this phenomenon, the result is called tumor dormancy, and when a single cancer cell undergoes this process, it is termed quiescence. Cancer stem cells (CSCs) share several overlapping characteristics and signaling pathways with dormant cancer cells, including therapy resistance, and an ability to metastasize and evade the immune system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.12.002DOI Listing
April 2020
3 Reads

Exploiting epigenetically mediated changes: Acute myeloid leukemia, leukemia stem cells and the bone marrow microenvironment.

Adv Cancer Res 2019 21;141:213-253. Epub 2019 Jan 21.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, United States. Electronic address:

Acute myeloid leukemia (AML) derives from the clonal expansion of immature myeloid cells in the bone marrow, and results in the disruption of normal hematopoiesis and subsequent bone marrow failure. The bone marrow microenvironment (BME) and its immune and other supporting cells are regarded to facilitate the survival, differentiation and proliferation of leukemia stem cells (LSCs), which enables AML cells to persist and expand despite treatment. Recent studies have identified epigenetic modifications among AML cells and BME constituents in AML, and have shown that epigenetic therapy can potentially reprogram these alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.12.005DOI Listing
April 2020
2 Reads

Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy.

Adv Cancer Res 2019 19;141:175-212. Epub 2018 Dec 19.

Institute for Cell Engineering, McKusick-Nathans Institute of Genetic Medicine, and Departments of Pediatrics, Medicine, Oncology, Radiation Oncology, and Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address:

Clinical studies have revealed that breast cancers contain regions of intratumoral hypoxia (reduced oxygen availability), which activates hypoxia-inducible factors (HIFs). The relationship between intratumoral hypoxia, distant metastasis and cancer mortality has been well established. A major mechanism by which intratumoral hypoxia contributes to disease progression is through induction of the breast cancer stem cell (BCSC) phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.11.001DOI Listing
April 2020
2 Reads

Assays for functionally defined normal and malignant mammary stem cells.

Adv Cancer Res 2019 17;141:129-174. Epub 2019 Jan 17.

Laboratory of Stem Cell and Cancer Biology, Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States. Electronic address:

The discovery of rare, heterogeneous self-renewing stem cells with shared developmental and molecular features within epithelial components of mammary gland and breast cancers has provided a conceptual framework to understand cellular composition of these tissues and mechanisms that control their number. These normal mammary epithelial stem cells (MaSCs) and breast cancer stem cells (BCSCs) were identified and analyzed using transplant assays (namely mammary repopulating unit (MRU) assay, mammary tumor-initiating cell (TIC) assay), which reveal their latent ability to regenerate respective normal and malignant epithelial tissues with self-renewing units displaying hierarchical cellular differentiation over multiple generations in recipient mice. "Next-generation" methods using "barcoded" normal and malignant mammary cells, with the help of next-generation sequencing (NGS) technology, have revealed hidden complexity and heterogeneous growth potential of MaSCs and BCSCs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.12.004DOI Listing
April 2020
4 Reads

Regulation of cancer stem cell properties by SIX1, a member of the PAX-SIX-EYA-DACH network.

Adv Cancer Res 2019 16;141:1-42. Epub 2019 Jan 16.

Center for Stem Cell Biology & Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, United States; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, United States; Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, United States; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, United States.

The PAX-SIX-EYA-DACH network (PSEDN) is a central developmental transcriptional regulatory network from Drosophila to humans. The PSEDN is comprised of four conserved protein families; including paired box (PAX), sine oculis (SIX), eyes absent (EYA), and dachshund (DACH). Aberrant expression of PSEDN members, particularly SIX1, has been observed in multiple human cancers, where SIX1 expression correlates with increased aggressiveness and poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.12.001DOI Listing
April 2020
4 Reads

Neutral Sphingomyelinases in Cancer: Friend or Foe?

Adv Cancer Res 2018 28;140:97-119. Epub 2018 May 28.

Department of Medicine and Cancer Center, Stony Brook University, Stony Brook, NY, United States.

For many years, neutral sphingomyelinases (N-SMases) were long thought to be anticancer enzymes owing to their roles as key producers of ceramide linked to apoptosis, growth arrest, and the chemotherapeutic response. However, in recent years, with the cloning of multiple isoforms and with new information on their cellular roles, particularly for nSMase2, a more complex picture is emerging suggesting that N-SMases have both pro- and anticancer roles. In this chapter, we will summarize current knowledge on N-SMase expression in cancer and the roles of N-SMase activity and specific isoforms in cancer-relevant biologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.04.010DOI Listing
September 2019
5 Reads

Role and Function of Sphingomyelin Biosynthesis in the Development of Cancer.

Adv Cancer Res 2018 29;140:61-96. Epub 2018 May 29.

Department of Physiology and Biophysics, Stony Brook University, Stony Brook, NY, United States.

Sphingomyelin (SM) biosynthesis represents a complex, finely regulated process, mostly occurring in vertebrates. It is intimately linked to lipid transport and it is ultimately carried out by two enzymes, SM synthase 1 and 2, selectively localized in the Golgi and plasma membrane. In the course of the SM biosynthetic reaction, various lipids are metabolized. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0065230X183003
Publisher Site
http://dx.doi.org/10.1016/bs.acr.2018.04.009DOI Listing
September 2019
25 Reads

Side Effects in Cancer Therapy: Are Sphingolipids to Blame?

Adv Cancer Res 2018 5;140:367-388. Epub 2018 Jun 5.

Department of Physiology, University of Kentucky, Lexington, KY, United States.

Cancer patients' quality of life is greatly dependent on the efficacy of treatments and their associated side effects, which can significantly reduce the overall quality of life. Although the effectiveness of cancer treatments has improved over time, adverse effects persist with each treatment. Some side effects, such as paclitaxel-induced peripheral neuropathy, can be dose limiting, thus further reducing the potential of paclitaxel chemotherapy treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.04.017DOI Listing
September 2019
36 Reads

Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Adv Cancer Res 2018 19;140:327-366. Epub 2018 Jun 19.

Department of Pharmacology, University of Virginia, Charlottesville, VA, United States; University of Virginia Cancer Center, University of Virginia, Charlottesville, VA, United States.

Sphingolipids are bioactive lipids that participate in a wide variety of biological mechanisms, including cell death and proliferation. The myriad of pro-death and pro-survival cellular pathways involving sphingolipids provide a plethora of opportunities for dysregulation in cancers. In recent years, modulation of these sphingolipid metabolic pathways has been in the forefront of drug discovery for cancer therapeutics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.acr.2018.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320700PMC
September 2019
4 Reads